Karuna raises $42m to advance KarXT into phase 2 study
The company’s announcement also included the issuance of $22m in shares upon conversion of debt into equity Participants included ARCH Venture Partners, the Wellcome Trust, Steven Paul M.D.,
These therapeutic antibodies include ‘blood-brain barrier (BBB)’ penetrating bispecific antibodies (BsAb) (VEGF/undisclosed BBB target BsAb, undisclosed target/undisclosed BBB target BsAb); immune cell engaging bispecific antibodies (4-1BB/undisclosed target BsAb,
This collaboration broadens AbbVie’s oncology research to access advanced precision medicine technology to expand the development of potentially life-changing treatments for patients with cancer. Chimeric Antigen Receptor T-cell